-
Product Insights
New![]()
Pivot Energy Clean Footprint Solar PV Park
Pivot Energy Clean Footprint Solar PV Park is a solar PV project located in Virginia, United States. The project is owned and being developed by Clean Footprint, LLC; Pivot Energy Group LLC. The project is at the permitting stage. Empower your strategies with our Pivot Energy Clean Footprint Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business...
-
Product Insights
New![]()
Pivot Energy Illinois Community Solar PV Park
Pivot Energy Illinois Community Solar PV Park is a solar PV project located in Illinois, United States. The project is owned and developed by Pivot Energy Group LLC. The project is currently under construction. Empower your strategies with our Pivot Energy Illinois Community Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding...
-
Product Insights
New![]()
Pivot Power Invinity LODES Demonstration Solar PV Park
Pivot Power Invinity LODES Demonstration Solar PV Park is a solar PV project located in United Kingdom. The project is owned and being developed by Invinity Energy Systems Plc; Pivot Power LLP. The project is at the permitting stage. Empower your strategies with our Pivot Power Invinity LODES Demonstration Solar PV Park report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3...
-
Company Insights
New![]()
Innovation and Patenting activity of Incitec Pivot Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Incitec Pivot Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Imatinib Mesylate in Pulmonary Arterial Hypertension
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Imatinib Mesylate in Pulmonary Arterial Hypertension Drug Details: Imatinib mesylate is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nemtabrutinib in B-Cell Non-Hodgkin Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in B-Cell Non-Hodgkin Lymphoma Drug Details: Nemtabrutinib (ARQ-531) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nemtabrutinib in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in Diffuse Large B-Cell Lymphoma Drug Details: Nemtabrutinib (ARQ-531) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nemtabrutinib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: Nemtabrutinib (ARQ-531) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nemtabrutinib in Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in Chronic Lymphocytic Leukemia (CLL) Drug Details: Nemtabrutinib (ARQ-531) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nemtabrutinib in Marginal Zone B-cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in Marginal Zone B-cell Lymphoma Drug Details: Nemtabrutinib (ARQ-531) is under development for the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.